Matthew Koshy to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications Matthew Koshy has written about Hematopoietic Stem Cell Transplantation.
Connection Strength
0.498
-
Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study. Haematologica. 2026 Jan 01; 111(1):177-183.
Score: 0.143
-
High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT). Eur J Haematol. 2024 Jul; 113(1):110-116.
Score: 0.131
-
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200?mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2018 07; 59(7):1666-1671.
Score: 0.084
-
Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. Biol Blood Marrow Transplant. 2016 Mar; 22(3):441-8.
Score: 0.072
-
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2034-41.
Score: 0.068